Loading…
Employees: 124
Size Design Therapeutics (DSGN) is a United States Health Care company (Biotechnology) with a market value of $639M, the 2550th largest of 3,117 United States companies the cockpit tracks. Shares closed at $10.21 on 6 Nov 2026.
Performance Over six months the shares fell 28.2%, against -13.7% for the median peer and -1.1% for the United States market (cap-weighted) — 6th lowest of 19 in its peer set.
Short interest Short interest is 10.6% of the free float (15 Oct 2026).
Next results Next results expected around 15 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Revenue growth | — | — | — | — | — |
| Gross profit | -$619,000 | -$622,000 | -$596,000 | -$537,000 | -$466,000 |
| EBITDA | -$78.7M | -$78.8M | -$61.8M | -$77.7M | -$67.1M |
| Net income | -$70.8M | -$69.8M | -$49.6M | -$66.9M | -$63.3M |
| Free cash flow | -$55.1M | -$54.6M | -$43.4M | -$58.8M | -$52.7M |
| Capital expenditure | $55,000 | $193,000 | $340,000 | $256,000 | $918,000 |
| Total debt | $2.66M | $1.53M | $2.33M | $3.05M | $3.69M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | DSGN | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -11.1% | -9.7% | 10th lowest of 21 |
| 6-month return | -28.2% | -13.7% | 6th lowest of 19 |
| Distance from 52-week high | -40.8% | -44.7% | 9th highest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Design Therapeutics DSGN | United States | $639M | -28% | n/a | n/a | n/a | n/a | n/a |
| Geron GERN | United States | $636M | -29% | +19% | -8% | 1.6× | n/a | n/a |
| Kura Oncology KURA | United States | $647M | -23% | -7% | -412% | 2.0× | n/a | n/a |
| Getein Biotech 603387.SS | China | $647M | -12% | +8% | 21% | 2.7× | -8.3% | -1.3% |
| Apnimed APMD | United States | $629M | n/a | +380% | -140% | 20.3× | n/a | n/a |
| Wave Life Sciences WVE | United States | $664M | -53% | -35% | -321% | 3.9× | n/a | n/a |
| Boji Medical Technology 300404.SZ | China | $664M | +7% | +32% | 4% | 4.1× | 35.4% | +27.2% |
| Ascletis Pharma 1672.HK | Hong Kong | $610M | -73% | -59% | -71,976% | 2,088.7× | n/a | n/a |
| Candel Therapeutics CADL | United States | $670M | +5% | n/a | n/a | n/a | n/a | n/a |
| 4D Molecular Therapeutics FDMT | United States | $677M | +21% | +278,712% | -214% | 3.9× | n/a | n/a |
| Aura Biosciences AURA | United States | $680M | -22% | n/a | n/a | n/a | n/a | n/a |
| Shenzhen Weiguang Biological Products 002880.SZ | China | $682M | -22% | 0% | 18% | 4.7× | n/a | n/a |
| Anhui Huaheng Biotechnology 688639.SS | China | $688M | -40% | +7% | 3% | 2.1× | n/a | n/a |
| Genfit GNFT.PA | France | $593M | +19% | +28% | -130% | 11.2× | 40.0% | +143.5% |
| Climb Bio CLYM | United States | $591M | -10% | n/a | n/a | n/a | n/a | n/a |
| Attovia Therapeutics ATTO | United States | $697M | +744% | n/a | -4,975% | 625.6× | n/a | n/a |
| Solid Biosciences SLDB | United States | $707M | -9% | n/a | n/a | n/a | n/a | n/a |
| Alebund Pharmaceuticals (Jiangsu) 9637.HK | Hong Kong | $576M | n/a | +674% | -495% | 25.7× | n/a | n/a |
| Sana Biotechnology SANA | United States | $709M | -32% | n/a | n/a | n/a | n/a | n/a |
| Faeth Therapeutics FTH | United States | $570M | -6% | n/a | n/a | n/a | n/a | n/a |
| Shouyao Holdings Beijing 688197.SS | China | $726M | -16% | +4,564% | -92% | 43.1× | n/a | n/a |